Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 19/20 | 0.51 |
| ▸ | METAP1 | P53582 | 9/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488107 | 1.00 | METAP2 (0.51) | METAP2METAP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11112714 | 0.76 | L3MBTL1 (0.37) | L3MBTL1 | |
| SCHEMBL11115955 | 0.75 | L3MBTL1 (0.36) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11109067 | 0.74 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL6478020 | 0.73 | METAP2 (0.60) | METAP2METAP1 | |
| SCHEMBL6485833 | 0.73 | METAP2 (0.60) | METAP2METAP1 | |
| SCHEMBL6490152 | 0.72 | METAP2 (0.53) | METAP2METAP1 | |
| SCHEMBL6238982 | 0.71 | METAP2 (0.57) | METAP2METAP1 | |
| SCHEMBL5847889 | 0.71 | METAP2 (0.57) | METAP2METAP1 | |
| SCHEMBL5848419 | 0.71 | METAP2 (0.57) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885L3MBTL1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.